Magnesium trisilicate

DB09281ApprovedSmall molecule

Magnesium trisilicate is an antacid used for the symptomatic treatment of peptic ulcers. A medication used to relieve heartburn and indigestion.

Mechanism: The gelatinous silicon dioxide, formed by the reaction of magnesium trisilicate with gastric contents is said to protect ulcerated mucosal surfaces and favor healing.
Curator reviewed
Primary indication: For the treatment of peptic ulcers.Curator reviewed · 8 structured indications
Formula / weight: Mg₂O₈Si₃ · 260.857 g/mol (avg)
First approval: Canada, 1966 · United States, 2011
Brand names: Gaviscon Chewable

Resolves to

Compound

Clinical / RWD

Structure

InChIKeyGXGAKHNRMVGRPK-UHFFFAOYSA-NSMILES[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O

What you can answer from here — as of August 30, 2026

1,296Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

8Structured indicationsCondition, population, route and combination as fields, not prose

106Marketed productsAcross 7 countries and 76 labellers

3+ReferencesStructured and connected to the statements they support

Which other approved drugs treat the same conditions as Magnesium trisilicate, and which companies have late-stage candidates in those indications?

Create a free account or log in to explore the full data card.